DEA Extends Telehealth Flexibility Pertaining to Controlled Substances
May 16, 2023
A pandemic-era policy that allows physicians to prescribe controlled substances in a telehealth visit has been extended to Nov. 11, 2023. Although the rule was set to expire with the end of the public health emergency on May 11, the Drug Enforcement Agency (DEA) has extended the temporary policy for telehealth prescribing of controlled substances, including those used to treat opioid use disorder.
The DEA initially sought to require patients to visit a physician or clinic within 30 days of receiving a prescription for a controlled substance. The proposed rule received public outcry, including from harm reduction experts who predicted that it would disrupt access to buprenorphine.
For more information, please contact us by email.
A pandemic-era policy that allows physicians to prescribe controlled substances in a telehealth visit has been extended to Nov. 11, 2023. Although the rule was set to expire with the end of the public health emergency on May 11, the Drug Enforcement Agency (DEA) has extended the temporary policy for telehealth prescribing of controlled substances, including those used to treat opioid use disorder.
The DEA initially sought to require patients to visit a physician or clinic within 30 days of receiving a prescription for a controlled substance. The proposed rule received public outcry, including from harm reduction experts who predicted that it would disrupt access to buprenorphine.
For more information, please contact us by email.